watsapp-num

Contact Info

Contact Us
United Kingdom — Post-Brexit Regulatory Guide

UK Drug Registration &
MHRA Regulatory Approval
— Complete Guidance

Navigate the post-Brexit UK regulatory landscape with confidence. Medwisdom Lifescience provides expert, end-to-end support for pharmaceutical, biologic, and medical device approvals under the MHRA — from pathway selection and dossier preparation to pharmacovigilance and post-approval compliance.

Get a Free Consultation Explore Our Services
200+ Successful MHRA Submissions
15+ Years Regulatory Experience
50+ Countries Served Globally
100% Compliance Track Record
Market Overview

Why the UK is a Priority Pharmaceutical Market

The United Kingdom is one of the world's most dynamic and innovation-driven markets for pharmaceuticals, biologics, medical devices, and biotechnology. Fuelled by robust NHS demand, world-class research institutions, and a mature life sciences ecosystem, the UK offers significant commercial opportunity for both multinational manufacturers and emerging biotech companies.

Post-Brexit, the regulatory landscape has fundamentally changed. The Medicines and Healthcare products Regulatory Agency (MHRA) now operates as a fully independent regulator, governing medicines and medical devices for Great Britain (England, Scotland, and Wales). Northern Ireland follows a separate, dual-framework pathway under both MHRA and EU (EMA) rules as defined by the Windsor Framework.

Key post-Brexit insight: Products previously approved under the European Centralised Procedure (EMA) must now be separately registered with the MHRA for continued sale in Great Britain. Understanding which pathway — NP, DCP, MRP, or the Innovative Licensing and Access Pathway (ILAP) — is best suited to your product is critical to a timely and cost-effective UK market entry.

Medwisdom Lifescience's UK regulatory specialists monitor every MHRA policy update and guidance revision, ensuring our clients always operate on the most current and compliant strategic footing.

Discuss Your UK Strategy
Regulatory Pathways

MHRA Approval Pathways for UK Drug Registration

Selecting the right submission route is the single most critical decision in your UK market entry strategy. Our regulatory experts evaluate your product profile, development stage, and commercial objectives to recommend the optimal pathway.

National Procedure (NP)

A standalone UK-only submission directly to the MHRA, ideal for products targeting Great Britain exclusively or those that do not qualify for EU recognition routes. Offers full MHRA control over the timeline and assessment.

Great Britain — Single Market

Decentralised Procedure (DCP)

For products not yet authorised in any EU/EEA state, DCP allows simultaneous submission across multiple reference and concerned member states. Relevant under the Windsor Framework for Northern Ireland market entry.

Multi-Country Launch

Mutual Recognition Procedure (MRP)

If your product already holds a marketing authorisation in an EU/EEA reference member state, the MRP allows recognition of that authorisation across other states — particularly relevant for Northern Ireland via the Windsor Framework.

EU/EEA Existing MA Holders

Innovative Licensing & Access Pathway (ILAP)

The MHRA's flagship innovation pathway offers early and intensive engagement, a Target Development Profile (TDP), and accelerated rolling review for promising new medicines addressing unmet medical needs.

Novel / Breakthrough Medicines

International Recognition Procedure (IRP)

A post-Brexit mechanism allowing the MHRA to recognise decisions from trusted regulators — including the FDA, EMA, Health Canada, TGA, and Swissmedic — to accelerate GB approvals without duplicating full assessments.

Recognised Foreign Approvals

UKCA Marking (Medical Devices)

Medical devices placed on the Great Britain market must bear UKCA marking and be registered on the MHRA's device registration database. Our specialists manage conformity assessments, technical files, and ongoing vigilance obligations.

UK MDR 2002 Compliance
Our UK Offerings

Comprehensive UK Regulatory Services by Medwisdom

From pre-submission strategy through to post-approval lifecycle management, Medwisdom Lifescience delivers an integrated suite of regulatory services purpose-built for the UK market. Our multi-disciplinary team combines scientific expertise, deep MHRA experience, and operational efficiency to keep your programme on track and on budget.

Every engagement begins with a thorough regulatory gap analysis and a clearly defined submission roadmap tailored to your product's unique profile and your organisation's commercial timeline.

Request a Quote
Regulatory Affairs & MHRA Submissions
End-to-end eCTD dossier preparation, gap analysis, scientific advice requests, and full submission management for NP, IRP, and ILAP pathways.
Medical Device Regulatory (UKCA)
UKCA marking support, conformity assessment, technical file compilation, MHRA device registration, and post-market vigilance under UK MDR 2002.
Pharmacovigilance & Safety
UK QPPV/local contact services, PSMF setup, ICSRs, signal detection, PSUR/PBRER preparation, and RMP development aligned with MHRA guidance.
Clinical Trial Support (CTA)
MHRA Clinical Trial Authorisation (CTA) submissions, protocol review, site management, monitoring, and regulatory compliance under UK clinical trial regulations.
Biometrics & Data Management
Statistical analysis planning, clinical data management, safety data review, and integrated regulatory reporting for MHRA submissions.
SmPC, PIL & Labelling
Development, review, and update of Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL), and labelling per UK-specific MHRA readability requirements.
Post-Approval Changes & Variations
Type I and Type II variations, renewals, urgent safety restrictions, and lifecycle management to maintain continuous compliance with your UK marketing authorisation.
Regulatory Strategy & Intelligence
Bespoke regulatory strategy development, pathway selection, MHRA scientific advice facilitation, and horizon scanning for UK post-Brexit regulatory changes.
How It Works

Our UK Drug Registration Process

A structured, milestone-driven approach that ensures regulatory certainty, minimises submission risk, and accelerates your path to MHRA approval.

1

Initial Assessment

Regulatory gap analysis, target market review, and product profile evaluation to define the optimal UK submission strategy.

2

Pathway Selection

Selection of the most appropriate MHRA procedure (NP, IRP, ILAP, DCP/MRP) and pre-submission meeting coordination with MHRA if required.

3

Dossier Preparation

Compilation of a complete eCTD-compliant CTD dossier covering Modules 1–5, with full quality, non-clinical, and clinical documentation.

4

MHRA Submission

Electronic submission via the MHRA portal, fee payment management, and formal acknowledgment tracking.

5

Review & Responses

Active management of MHRA questions, Day 70/120/150 responses, and consolidated List of Outstanding Issues (LOI) resolution.

6

Approval & Launch

Marketing Authorisation (MA) grant, post-approval pharmacovigilance setup, and ongoing lifecycle compliance management.

Why Medwisdom

Your Dedicated UK Regulatory Partner

MHRA-Experienced Regulatory Scientists

Our team includes regulatory professionals with direct MHRA submission experience across pharmaceuticals, biologics, generics, and medical devices.

Post-Brexit Pathway Expertise

We stay ahead of every MHRA guidance update, Windsor Framework development, and IRP recognition list change so you don't have to.

Faster Time-to-Market

Our structured project management and pre-submission engagement strategy minimise avoidable delays and clock stops during MHRA assessment.

Integrated Global Regulatory Strategy

We align your UK programme with simultaneous EU, US, and rest-of-world submissions for maximum efficiency and regulatory coherence.

Full-Spectrum UK Coverage

Medwisdom supports the complete UK regulatory lifecycle — from first-in-human clinical trials to mature post-market surveillance and lifecycle variation management.

Product Categories We Support

Chemical NCEs Biologics & Biosimilars Generic Medicines ATMPs Medical Devices (UKCA) Combination Products OTC & Self-Care Cosmeceuticals
Start Your UK Journey
FAQs

UK Drug Registration — Frequently Asked Questions

Answers to the most common questions our clients ask about MHRA submissions, post-Brexit regulations, and UK market entry timelines.

Ask a Specific Question
Post-Brexit, the MHRA operates as a fully independent regulator for Great Britain (England, Scotland, Wales). An EMA centralised authorisation no longer automatically grants access to the GB market. Products must be separately submitted to and approved by the MHRA via the National Procedure, IRP, or ILAP. Northern Ireland retains a dual-access framework under the Windsor Framework, allowing EMA-approved products to circulate without additional GB registration.
A standard MHRA National Procedure assessment runs 210 active days, with clock stops when additional information is requested. In practice, end-to-end timelines from submission to approval typically range from 12 to 18 months depending on product complexity, dossier quality, and the number of MHRA questions raised. Products eligible for the IRP (International Recognition Procedure) can achieve approval in as little as 67 active days if a qualifying reference authorisation is in place.
Yes. The Marketing Authorisation Holder (MAH) for a Great Britain marketing authorisation must be established in the UK or, under certain transitional provisions, in Northern Ireland or a country on the MHRA's approved list. Additionally, a UK-resident Qualified Person for Pharmacovigilance (QPPV) and a UK-registered local contact person for pharmacovigilance are mandatory. Medwisdom can advise on suitable UK representation and QPPV arrangements.
ILAP is the MHRA's accelerated access scheme for medicines offering significant clinical advantages over existing treatments or addressing unmet medical need. It provides a Target Development Profile (TDP), early scientific advice, rolling review of data modules, and a coordinated approach with NHS bodies to facilitate rapid patient access post-approval. ILAP is particularly well suited to oncology, rare diseases, and advanced therapy medicinal products (ATMPs).
An MHRA eCTD submission must include all five CTD modules: Module 1 (UK-specific administrative information including application form, SmPC, PIL, labelling, and fees), Module 2 (overviews and summaries), Module 3 (quality/pharmaceutical data), Module 4 (non-clinical study reports), and Module 5 (clinical study reports). The submission must comply with current MHRA eCTD validation criteria and ICH M4 guidance.
The MHRA's International Recognition Procedure (IRP) allows recognition of marketing authorisations granted by a select group of reference regulators including the EMA (Centralised Procedure), FDA, Health Canada, TGA, Swissmedic, and others. The IRP offers a significantly shorter assessment timeline (67 active days for most applications) and avoids the need to conduct a full re-assessment of previously reviewed data. Medwisdom evaluates IRP eligibility as a priority for clients with established global approvals.
Ready to Enter the UK Market?

Partner with Medwisdom for MHRA Regulatory Success

From initial regulatory strategy through to long-term post-market compliance, our expert team is ready to deliver a tailored, efficient, and compliant UK regulatory programme for your product portfolio.

Contact Our UK Regulatory Experts Call +91-9264127040